Coho Partners Ltd. Has $37.94 Million Position in Cencora, Inc. $COR

Coho Partners Ltd. decreased its stake in Cencora, Inc. (NYSE:COR) by 43.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 121,408 shares of the company’s stock after selling 92,180 shares during the period. Cencora makes up 4.9% of Coho Partners Ltd.’s portfolio, making the stock its 2nd largest holding. Coho Partners Ltd.’s holdings in Cencora were worth $37,944,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the period. Geode Capital Management LLC raised its position in shares of Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after buying an additional 284,229 shares during the last quarter. Norges Bank bought a new stake in shares of Cencora in the second quarter valued at about $695,215,000. Viking Global Investors LP lifted its stake in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the period. Finally, Amundi grew its position in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after buying an additional 249,742 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of NYSE:COR opened at $339.86 on Tuesday. The business’s fifty day moving average price is $346.94 and its two-hundred day moving average price is $313.70. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The stock has a market capitalization of $65.93 billion, a price-to-earnings ratio of 42.75, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the business earned $3.34 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Analyst Ratings Changes

Several equities analysts have commented on the company. UBS Group upped their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Barclays started coverage on Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a report on Monday, December 15th. Finally, Robert W. Baird set a $392.00 price objective on shares of Cencora in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $373.25.

Insiders Place Their Bets

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 20,317 shares of company stock valued at $7,009,260. 10.80% of the stock is currently owned by insiders.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.